Erratum: The emerging role of Twist proteins in hematopoietic cells and hematological malignancies (Blood Cancer Journal (2014) 4 (e206) DOI:10.1038/bcj.2014.22);The emerging role of Twist proteins in hematopoietic cells and hematological malignancies

Blood Cancer Journal

Volumn 4, Issue 4, 2014, Pages

  Merindol, N ^a   Riquet, A ^a   Szablewski, V ^b,c   Eliaou, J F ^b,c   Puisieux, A ^d   Bonnefoy, N ^b  

^a CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HELIX LOOP HELIX PROTEIN; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; TRANSCRIPTION FACTOR TWIST2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; CANCER SURVIVAL; CARCINOGENESIS; CELL LINE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; MESENCHYME CELL; MONOCYTE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PROTEIN FAMILY; REVIEW; RISK FACTOR; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; ANIMAL; HEMATOLOGIC DISEASE; METABOLISM;

ANIMALS; HEMATOLOGIC NEOPLASMS; HUMANS; TWIST TRANSCRIPTION FACTOR;

EID: 84901945527     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.81     Document Type: Erratum

References (121)

1. el Ghouzzi V, Le Merrer M, Perrin-Schmitt F, Lajeunie E, Benit P, Renier D et al. Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet 1997; 15: 42-46.
2. Howard TD, Paznekas WA, Green ED, Chiang LC, Ma N, Ortiz de Luna RI et al. Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. Nat Genet 1997; 15: 36-41.
3. Hebrok M, Wertz K, Fü chtbauer EM. M-twist is an inhibitor of muscle differentiation. Dev Biol 1994; 165: 537-544.
4. Lee YS, Lee HH, Park J, Yoo EJ, Glackin CA, Choi YI et al. Twist2, a novel ADD1/SREBP1c interacting protein, repRes.ses the transcriptional activity of ADD1/SREBP1c. Nucleic Acids Res. 2003; 31: 7165-7174.
5. Spicer DB, Rhee J, Cheung WL, Lassar AB. Inhibition of myogenic bHLH and MEF2 transcription factors by the bHLH protein Twist. Science 1996; 272: 1476-1480.
6. Murray SS, Glackin CA, Winters KA, Gazit D, Kahn AJ, Murray EJ. ExpRes.sion of helix-loop-helix regulatory genes during differentiation of mouse osteoblastic cells. J Bone Miner Res. 1992; 7: 1131-1138.
7. Tukel T,S? os?ić D, Al-Gazali LI, Erazo M, Casasnovas J, Franco HL et al. Homozygous nonsense mutations in TWIST2 cause Setleis syndrome. Am J Hum Genet 2010; 87: 289-296.
8. Sosic D, Richardson JA, Yu K, Ornitz DM, Olson EN. Twist regulates cytokine gene expRes.sion through a negative feedback loop that repRes.ses NF-kappaB activity. Cell 2003; 112: 169-180.
9. Thisse C, Perrin-Schmitt F, Stoetzel C, Thisse B. Sequence-specific transactivation of the Drosophila twist gene by the dorsal gene product. Cell 1991; 65: 1191-1201.
10. Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M et al. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 2008; 283: 14665-14673.
11. Howe LR, Watanabe O, Leonard J, Brown AM. Twist is up-regulated in Res.ponse to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res. 2003; 63: 1906-1913.
12. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 2008; 10: 295-305.
13. Gort EH, van Haaften G, Verlaan I, Groot AJ, Plasterk RH, Shvarts A et al. The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha. Oncogene 2008; 27: 1501-1510.
14. Hamamori Y, Sartorelli V, Ogryzko V, Puri PL, Wu HY, Wang JY et al. Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell 1999; 96: 405-413.
15. Gong XQ, Li L. Dermo-1, a multifunctional basic helix-loop-helix protein, repRes.ses MyoD transactivation via the HLH domain, MEF2 interaction, and chromatin deacetylation. J Biol Chem 2002; 277: 12310-12317.
16. Pan D, Fujimoto M, Lopes A, Wang YX. Twist-1 is a PPARdelta-inducible, negative-feedback regulator of PGC-1alpha in brown fat metabolism. Cell 2009; 137: 73-86.
17. Murre C, McCaw PS, Baltimore D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 1989; 56: 777-783.
18. Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N et al. A twist code determines the onset of osteoblast differentiation. Dev Cell 2004; 6: 423-435.
19. Koh HS, Lee C, Lee KS, Ham CS, Seong RH, Kim SS et al. CD7 expRes.sion and galectin-1-induced apoptosis of immature thymocytes are directly regulated by NF-kappaB upon T-cell activation. Biochem Biophys Res. Commun 2008; 370: 149-153.
20. Hong J, Zhou J, Fu J, He T, Qin J, Wang L et al. Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness. Cancer Res. 2011; 71: 3980-3990.
21. Xue G, Res.tuccia DF, Lan Q, Hynx D, Dirnhofer S, Hess D et al. Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-b signaling axes. Cancer Discov 2012; 2: 248-259.
22. Firulli BA, Howard MJ, McDaid JR, McIlreavey L, Dionne KM, Centonze VE et al. PKA, PKC, and the protein phosphatase 2A influence HAND factor function: a mechanism for tissue-specific transcriptional regulation. Mol Cell 2003; 12: 1225-1237.
23. Firulli AB, Conway SJ. Phosphoregulation of Twist1 provides a mechanism of cell fate control. Curr Med Chem 2008; 15: 2641-2647. Review.
24. Vichalkovski A, GRes.ko E, Hess D, Res.tuccia DF, Hemmings BA. PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in Res.ponse to DNA damage. Oncogene 2010; 29: 3554-3565.
25. Castanon I, Von Stetina S, Kass J, Baylies MK. Dimerization partners determine the activity of the Twist bHLH protein during Drosophila mesoderm development. Development 2001; 128: 3145-3159.
26. Yan W, Young AZ, SoaRes. VC, Kelley R, Benezra R, Zhuang Y. High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice. Mol Cell Biol 1997; 17: 7317-7327.
27. Connerney J, Andreeva V, Leshem Y, Mercado MA, Dowell K, Yang X et al. Twist1 homodimers enhance FGF Res.ponsiveness of the cranial sutuRes. and promote suture closure. Dev Biol 2008; 318: 323-334.
28. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 1990; 61: 49-59.
29. Hayashi M, Nimura K, Kashiwagi K, Harada T, Takaoka K, Kato H et al. Comparative roles of Twist-1 and Id1 in transcriptional regulation by BMP signaling. J Cell Sci 2007; 120: 1350-1357.
30. Danciu TE, Whitman M. Oxidative stRes.s drives disulfide bond formation between basic helix-loop-helix transcription factors. J Cell Biochem 2010; 109: 417-424.
31. Sharabi AB, Aldrich M, Sosic D, Olson EN, Friedman AD, Lee SH et al. Twist-2 controls myeloid lineage development and function. PLoS Biol 2008; 6: e316.
32. Koh HS, Lee C, Lee KS, Park EJ, Seong RH, Hong S et al. Twist2 regulates CD7 expRes.sion and galectin-1-induced apoptosis in mature T-cells. Mol Cells 2009; 28: 553-558.
33. Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, Olson EN et al. Twist mediates suppRes.sion of inflammation by type I IFNs and Axl. J Exp Med 2006; 203: 1891-1901.
34. Li X, Marcondes AM, Gooley TA, Deeg HJ. The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes. Blood 2010; 116: 2304-2314.
35. Cosset E, Hamdan G, Jeanpierre S, Voeltzel T, Sagorny K, Hayette S et al. Deregulation of TWIST-1 in the CD34\+ compartment repRes.ents a novel prognostic factor in chronic myeloid leukemia. Blood 2011; 117: 1673-1676.
36. Wang SM, Coljee VW, Pignolo RJ, Rotenberg MO, Cristofalo VJ, Sierra F. Cloning of the human twist gene: its expRes.sion is retained in adult mesodermallyderived tissues. Gene 1997; 187: 83-92.
37. Mabbott NA, Kenneth Baillie J, Kobayashi A, Donaldson DS, Ohmori H, Yoon SO et al. ExpRes.sion of mesenchyme-specific gene signatuRes. by follicular dendritic cells: insights from the meta-analysis of microarray data from multiple mouse cell populations. Immunology 2011; 133: 482-498.
38. Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008; 73: 975-983. Review.
39. Wan YY. Multi-tasking of helper T cells. Immunology 2010; 130: 166-171. Review.
40. Niesner U, Albrecht I, Janke M, Doebis C, Loddenkemper C, Lexberg MH et al. Autoregulation of Th1-mediated inflammation by twist1. J Exp Med 2008; 205: 1889-1901.
41. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939.
42. Pham D, Vincentz JW, Firulli AB, Kaplan MH. Twist1 regulates Ifng expRes.sion in Th1 cells by interfering with Runx3 function. J Immunol 2012; 189: 832-840.
43. Pham D, Walline CC, Hollister K, Dent AL, Blum JS, Firulli AB et al. The transcription factor Twist1 limits T helper 17 and T follicular helper cell development by repRes.sing the gene encoding the interleukin-6 receptor a chain. J Biol Chem 2013; 288: 27423-27433.
44. Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3877-3885.
45. Nguyen CT, Gonzales FA, Jones PA. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res. 2001; 29: 4598-4606.
46. Puisieux A, Valsesia-Wittmann S, Ansieau S. A twist for survival and cancer progRes.sion. Br J Cancer 2006; 94: 13-17. Review.
47. Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008; 14: 79-89.
48. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999; 13: 2207-2217.
49. Stasinopoulos IA, Mironchik Y, Raman A, Wildes F, Winnard Jr P, Raman V. HOXA5-twist interaction alters p53 homeostasis in breast cancer cells. J Biol Chem 2005; 280: 2294-2299.
50. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A et al. Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene 2008; 27: 5543-5553.
51. Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas AC, Combaret V et al. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 2004; 6: 625-630.
52. Haque I, Banerjee S, Mehta S, De A, Majumder M, Mayo MS et al. Cysteine-rich 61-connective tissue growth factor-nephroblastoma-overexpRes.sed 5 (CCN5)/Wnt-1-induced signaling protein-2 (WISP-2) regulates microRNA-10b via hypoxia-inducible factor-1a-TWIST signaling networks in human breast cancer cells. J Biol Chem 2011; 286: 43475-43485.
53. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and Res.istance to paclitaxel. Cancer Res. 2007; 67: 1979-1987.
54. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A et al. Twist pomotes tumor cell growth through YB-1 expRes.sion. Cancer Res. 2008; 68: 98-105.
55. Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT et al. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol Res.istance in human cancer cells. Oncogene 2004; 23: 474-482.
56. Zhang X, Wang Q, Ling MT, Wong YC, Leung SC, Wang X. Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol Res.istance in nasopharyngeal carcinoma cells. Int J Cancer 2007; 120: 1891-1898.
57. Zhan X, Feng X, Kong Y, Chen Y, Tan W. JNK signaling maintains the mesenchymal properties of multi-drug Res.istant human epidermoid carcinoma KB cells through snail and twist1. BMC Cancer 2013; 13: 180.
58. Pham CG, Bubici C, Zazzeroni F, Knabb JR, Papa S, Kuntzen C et al. Upregulation of Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs. Mol Cell Biol 2007; 27: 3920-3935.
59. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890. Review.
60. Stirewalt DL, Mhyre AJ, Marcondes M, Pogosova-Agadjanyan E, Abbasi N, Radich JP et al. Tumour necrosis factor-induced gene expRes.sion in human marrow stroma: clues to the pathophysiology of MDS? Br J Haematol 2008; 140: 444-453.
61. Li X, Xu F, Chang C, Byon J, Papayannopoulou T, Deeg HJ et al. Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes. Haematologica 2013; 98: 414-419.
62. Kawagoe H, Kandilci A, Kranenburg TA, Grosveld GC. OverexpRes.sion of N-Myc rapidly causes acute myeloid leukemia in mice. Cancer Res. 2007; 67: 10677-10685.
63. Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sato Y et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 1999; 93: 1355-1363.
64. Kim MS, Kim GM, Choi YJ, Kim HJ, Kim YJ, Jin W. TrkC promotes survival and growth of leukemia cells through Akt-mTOR-dependent up-regulation of PLK-1 and Twist-1. Mol Cells 2013; 36: 177-184.
65. Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpRes.sion of AXL confers drug Res.istance in acute myeloid leukemia. Cancer Lett. 2008; 268: 314-324.
66. Sanchez-Correa B, Bergua JM, Campos C, Gayoso I, Arcos MJ, Bañ as H et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine 2013; 61: 885-891.
67. Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange BJ, Tweardy DJ et al. FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report. Blood 2013; 121: 1083-1093.
68. Tipping AJ, Deininger MW, Goldman JM, Melo JV. Comparative gene expRes.sion profile of chronic myeloid leukemia cells innately Res.istant to imatinib mesylate. Exp Hematol 2003; 31: 1073-1080.
69. Xin H, Kong Y, Jiang X, Wang K, Qin X, Miao ZH et al. Multi-drug-Res.istant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumorinitiating-cell properties. J Pharmacol Sci 2013; 122: 299-304.
70. Dulmage BO, Geskin LJ. Lessons learned from gene expRes.sion profiling of cutaneous T-cell lymphoma. Br J Dermatol 2013; 169: 1188-1197. Review.
71. Dippel E, Assaf C, Hummel M, Schrag HJ, Stein H, Goerdt S et al. Clonal T-cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in advanced cutaneous T-cell lymphoma: a critical evaluation. J Pathol 1999; 188: 146-154.
72. Eriksen KW, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, Geisler C et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expRes.sion and growth of leukemic Sezary cells. Leukemia 2001; 15: 787-793.
73. Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 1996; 93: 9148-9153.
74. Izban KF, Ergin M, Qin JZ, Martinez RL, Pooley RJ JR, Saeed S et al. Constitutive expRes.sion of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis Res.istance and pathogenesis. Hum Pathol 2000; 31: 1482-1490.
75. Kadin ME, Cavaille-Coll MW, Gertz R, Massagué J, Cheifetz S, George D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci USA 1994; 91: 6002-6006.
76. Scarisbrick JJ, Woolford AJ, Calonje E, Photiou A, Ferreira S, Orchard G et al. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and Sezary syndrome. J Invest Dermatol 2002; 118: 493-499.
77. van Doorn R, Dijkman R, Vermeer MH, Out-Luiting JJ, van der Raaij-Helmer EM, Willemze R et al. Aberrant expRes.sion of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sé zary syndrome identified by gene expRes.sion analysis. Cancer Res. 2004; 64: 5578-5586.
78. Ni X, Richmond HM, Liao XM, Decker WK, Shiue LH, Shpall EJ et al. Induction of T-cell Res.ponses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. J Invest Dermatol 2008; 128: 2631-2639.
79. Goswami M, Duvic M, Dougherty A, Ni X. Increased Twist expRes.sion in advanced stage of mycosis fungoides and Sézary syndrome. J Cutan Pathol 2012; 39: 500-507.
80. Michel L, Jean-Louis F, Begue E, Bensussan A, Bagot M. Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expRes.sion combination for reliable Sé zary syndrome diagnosis. Blood 2013; 121: 1477-1478.
81. Pace KE, Hahn HP, Pang M, Nguyen JT, Baum LG. CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death. J Immunol 2000; 165: 2331-2334.
82. Rappl G, Abken H, Muche JM, Sterry W, Tilgen W, André S et al. CD4\+CD7-leukemic T cells from patients with Sé zary syndrome are protected from galectin-1-triggered T cell death. Leukemia 2002; 16: 840-845.
83. Liu TY, Chen CY, Tien HF, Lin CW. Loss of CD7, independent of galectin-3 expRes.sion, implies a worse prognosis in adult T-cell leukaemia/lymphoma. Histopathology 2009; 54: 214-220.
84. Amin HM, Lai R. Pathobiology of ALK\+ anaplastic large-cell lymphoma. Blood 2007; 110: 2259-2267. Review.
85. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11-23. Review.
86. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002; 21: 1038-1047.
87. Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arRes.t in ALK-positive anaplastic large cell lymphoma. Oncogene 2004; 23: 5426-5434.
88. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005; 11: 623-629.
89. Zhang J, Wang P, Wu F, Li M, Sharon D, Ingham RJ et al. Aberrant expRes.sion of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. Cell Signal. 2012; 24: 852-858.
90. Degerman S, Siwicki JK, Osterman P, Lafferty-Whyte K, Keith WN, Roos G. Telomerase upregulation is a postcrisis event during senescence bypass and immortalization of two Nijmegen breakage syndrome T cell cultuRes.. Aging Cell 2010; 9: 220-235.
91. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expRes.sion profiling. Nature 2000; 403: 503-511.
92. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expRes.sion-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991-9996.
93. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861-1874.
94. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008; 111: 3701-3713.
95. Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28: 3360-3365.
96. Klapper W, Stoecklein H, Zeynalova S, Ott G, Kosari F, Rosenwald A et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008; 22: 2226-2229.
97. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci 2008; 100: 233-237.
98. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114: 3533-3537.
99. Lemma S, Karihtala P, Haapasaari KM, Jantunen E, Soini Y, Bloigu R et al. Biological roles and prognostic values of the epithelial-mesenchymal transitionmediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma. Histopathology 2013; 62: 326-333.
100. Hanzawa K, Momose S, Higashi M, Tokuhira M, Watanabe R, Kajino K et al. Y-box binding protein-1 expRes.sion in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era. Leuk Lymphoma 2010; 51: 2054-2062.
101. Xu W, Zhou L, Qin R, Tang H, Shen H. Nuclear expRes.sion of YB-1 in diffuse large B-cell lymphoma: correlation with disease activity and patient outcome. Eur J Haematol 2009; 83: 313-319.
102. Cameron EE, Baylin SB, Herman JG. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood 1999; 94: 2445-2451.
103. Melki JR, Vincent PC, Brown RD, Clark SJ. Hypermethylation of E-cadherin in leukemia. Blood 2000; 95: 3208-3213.
104. Thathia SH, Ferguson S, Gautrey HE, van Otterdijk SD, Hili M, Rand V et al. Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica 2012; 97: 371-378.
105. Blyth K, Slater N, Hanlon L, Bell M, Mackay N, Stewart M et al. Runx1 promotes B-cell survival and lymphoma development. Blood Cells Mol Dis 2009; 43: 12-19.
106. Stilgenbauer S, Bullinger L, Lichter P, Dö hner H. German CLL Study Group (GCLLSG) Chronic lymphocytic leukemia. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 2002; 16: 993-1007. Review.
107. Dö hner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. p53 gene deletion predicts for poor survival and non-Res.ponse to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
108. Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, Byrd PJ et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999; 353: 26-29.
109. Lin K, Manocha S, Harris RJ, Matrai Z, Sherrington PD, Pettitt AR. High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment. Blood 2003; 102: 1145-1146.
110. Damle RN, Wasil T, Fais F, Ghiotto F, VaLett.o A, Allen SL et al. Ig V gene mutation status and CD38 expRes.sion as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
111. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggRes.sive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
112. Rush LJ, Raval A, Funchain P, Johnson AJ, Smith L, Lucas DM et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res. 2004; 64: 2424-2433.
113. Schwartz R, Engel I, Fallahi-Sichani M, Petrie HT, Murre C. Gene expRes.sion patterns define novel roles for E47 in cell cycle progRes.sion, cytokine-mediated signaling, and T lineage development. Proc Natl Acad Sci USA 2006; 103: 9976-9981.
114. Lietz A, Janz M, Sigvardsson M, Jundt F, Dö rken B, Mathas S. Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers Res.istance to apoptosis. Br J Haematol 2007; 137: 342-348.
115. Mathas S, Janz M, Hummel F, Hummel M, Wollert-Wulf B, Lusatis S et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 2006; 7: 207-215.
116. Suh HC, Leeanansaksiri W, Ji M, Klarmann KD, Renn K, Gooya J et al. Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo. Oncogene 2008; 27: 5612-5623.
117. Yu WP, Scott SA, Dong WF. Induction of ID1 expRes.sion and apoptosis by the histone deacetylase inhibitor (trichostatin A) in human acute myeloid leukaemic cells. Cell Prolif 2008; 41: 86-97.
118. Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS et al. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood 2011; 117: 862-871.
119. Wang H, Wang XQ, Xu XP, Lin GW. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome. Leuk Res. 2010; 34: 598-604.
120. Bellido M, Avent?́n A, Lasa A, Estivill C, Carnicer MJ, Pons C et al. Id4 is deregulated by a t(6;14)(p22;q32) chromosomal translocation in a B-cell lineage acute lymphoblastic leukemia. Haematologica 2003; 88: 994-1001.
121. Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppRes.sor gene in human leukemia. Nat Genet 2005; 37: 265-274.